Physician profile
Jerome E Thurman
NPI 1194793943
$312,012.15
in general payments reported to CMS, 2019-2025
22 companies · $20K in 2025
The $20K reported for 2025 was more than what 93% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $79K · 2020: $40K · 2021: $61K · 2022: $67K · 2023: $38K · 2024: $5,575 · 2025: $20K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $42K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $13K · Food and Beverage: $5,391 · Travel and Lodging: $3,986 · Education: $24.04.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $41,720.50 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $13,300.00 |
| Food and Beverage | $5,390.60 |
| Travel and Lodging | $3,986.08 |
| Education | $24.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $118,002.56 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals Lp | $62,905.18 | 2019-2024 | Farxiga, Lokelma |
| Sanofi-Aventis U.S. LLC | $59,002.31 | 2019-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $37,193.49 | 2021-2024 | |
| Dexcom, INC. | $18,393.70 | 2019-2025 | Dexcom G7 Gss (161), Dexcom G6 Transmitter |
| Medtronic, INC. | $6,233.88 | 2021-2025 | Minimed 780g, Inpen Smart Insulin Delivery System, Inceptiv |
| Boehringer Ingelheim Pharmaceuticals, INC. | $3,750.00 | 2019 | |
| Medtronic Minimed, INC. | $2,096.27 | 2019-2020 | |
| Abbott Laboratories | $2,059.61 | 2021-2025 | Freestyle Libre 3 |
| Sequel Med Tech, LLC | $658.42 | 2025 | Twiist |
| Lilly USA, LLC | $547.30 | 2019-2025 | Mounjaro, Zepbound |
| Insulet Corporation | $380.84 | 2019-2022 | |
| Mannkind Corporation | $278.99 | 2019-2022 | |
| Ascendis Pharma Endocrinology INC | $186.24 | 2023-2025 | Yorvipath |
| Amgen INC. | $122.43 | 2024 | Evenity |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Antares Pharma, INC. | $72.49 | 2019 | |
| Pfizer INC. | $30.96 | 2024 | |
| Amneal Pharmaceuticals LLC | $30.02 | 2025 | Unithroid |
| Neurocrine Biosciences, INC. | $24.04 | 2025 | |
| Abbvie INC. | $16.93 | 2025 | |
| Rhythm Pharmaceuticals, INC. | $14.64 | 2025 | Imcivree |
| Janssen Pharmaceuticals, INC | $11.85 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jerome Thurman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.